(Q50030507)

23 February 2018

title

CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells (English)

1 reference

23 February 2018

0 references

0 references

1 reference

Yongping Zhang

1

1 reference

23 February 2018

Xingying Zhang

2

1 reference

23 February 2018

Chen Cheng

3

1 reference

23 February 2018

Wei Mu

4

1 reference

23 February 2018

Xiaojuan Liu

5

1 reference

23 February 2018

Na Li

6

1 reference

23 February 2018

Xiaofei Wei

7

1 reference

23 February 2018

Xiang Liu

8

1 reference

23 February 2018

Changqing Xia

9

1 reference

23 February 2018

Haoyi Wang

10

1 reference

23 February 2018

publication date

17 June 2017

1 reference

23 February 2018

published in

Frontiers of medicine

1 reference

23 February 2018

volume

11

1 reference

23 February 2018

issue

4

1 reference

23 February 2018

page(s)

554-562

1 reference

23 February 2018

CAR T cells for solid tumors: armed and ready to go?

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

LAG-3, a novel lymphocyte activation gene closely related to CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Role of LAG-3 in regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

LAG-3 regulates plasmacytoid dendritic cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

The CD4-like molecule LAG-3, biology and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Easy quantitative assessment of genome editing by sequence trace decomposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

DNA targeting specificity of RNA-guided Cas9 nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-017-0543-6

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28625015

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11684-017-0543-6

1 reference

23 February 2018

1 reference

23 February 2018